Cash flows from operating activities: | |
Net income | -6.48M |
Adjustments to reconcile net income to net cash (used in) provided by operating activities: | |
Decrease in accrued investment income | |
Depreciation and amortization | |
Amortization of intangible assets | |
Change in value / loss on value of UBS option to put securities | |
Auction rate securities mark to market, trading gain | |
Provision for doubtful accounts | 223K |
Excess and obsolete inventory | |
Deferred income taxes | |
Stock-based compensation | 3.48M |
Unrealized (gain)/loss on foreign exchange | |
Changes in operating assets and liabilities, net | |
Accounts receivable | 12.95M |
Inventories | -2.41M |
Prepaid expenses and other assets | 1.56M |
Accounts payable | -3.15M |
Accrued compensation and benefits | -7.32M |
Restructuring liabilities | |
Accrued warranty | |
Deferred revenue, net | |
Deferred distributors revenue, net of cost of sales to distributors | |
Other accrued liabilities | |
Other long-term liabilities | -842K |
Net cash (used in) provided by operating activities | 9.57M |
Cash flows used in investing activities: | |
Capital expenditures | -1.64M |
Purchases of investments | |
Proceeds from maturities of investments and marketable securities | |
Proceeds from sales of investments and marketable securities | |
Net cash used in investing activities | -1.64M |
Cash flows provided by financing activities: | |
Proceeds from issuance of common stock | 3.42M |
Net cash provided by financing activities | 166K |
Foreign currency effect on cash | 38K |
Net decrease in cash and cash equivalents | 8.14M |
Cash and cash equivalents at beginning of period | 94.12M |
Cash and cash equivalents at end of period | 102.27M |